Overview

Open-label, Flexible-dose Study of Vortioxetine in Patients With Depression in India

Status:
Recruiting
Trial end date:
2022-03-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of flexible doses of vortioxetine (5 - 20 mg/day) over a period of 12 weeks in patients with depression in India
Phase:
Phase 4
Details
Lead Sponsor:
H. Lundbeck A/S
Treatments:
Vortioxetine